Methocarbamol


Generic Medicine Info
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contraindications
Brain damage; epilepsy; myasthenia gravis, coma or pre-coma states. Renal impairment (inj).
Special Precautions
Patient must be in a recumbent position during and for at least 10-15 minutes after administration (IV). Renal (oral) and hepatic impairment. Children (when used in tetanus) and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs of bradycardia, hypotension; extravasation (IV).
Adverse Reactions
Significant: CNS depression. Blood and lymphatic system disorders: Leucopenia. Cardiac disorders: Bradycardia. Ear and labyrinth disorders: Vertigo. Eye disorders: Blurred vision, nystagmus, diplopia, conjunctivitis. Gastrointestinal disorders: Dyspepsia, nausea, vomiting, metallic taste. General disorders and administration site conditions: Fever; inj site pain and sloughing (IV/IM). Hepatobiliary disorders: Jaundice (including cholestatic jaundice). Immune system disorders: Hypersensitivity reactions (e.g. anaphylaxis, angioedema). Nervous system disorders: Headache, seizures, mild muscular incoordination, dizziness, drowsiness. Psychiatric disorders: Confusion, amnesia, insomnia. Respiratory, thoracic and mediastinal disorders: Nasal congestion. Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria. Vascular disorders: Flushing, hypotension, syncope, thrombophlebitis.
Drug Interactions
May potentiate the effects of other CNS depressants and stimulants (e.g. barbiturates, anaesthetics, appetite suppressants), anticholinergics (e.g. atropine) and certain psychotropic drugs. May suppress the effect of pyridostigmine bromide.
CIMS Class
Muscle Relaxants
ATC Classification
M03BA03 - methocarbamol ; Belongs to the class of carbamic esters. Used as centrally-acting muscle relaxants.
Disclaimer: This information is independently developed by CIMS based on methocarbamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in